BCR and chronic myelogenous leukemia, BCR-ABL1 positive: In this work, we investigated whether SPOA dephosphorylated BCR-ABL Y177 and degraded BCR-ABL protein in ubiquitin-independent manner, and whether SPOA depressed the oncogenecity of BCR-ABL in imatinib sensitive and resistant CML cells and the underlying molecular mechanisms.